EUVIMEDEUVIMED entdecken
VergleichsstudiePragmatische StudieOpen Access · CC BY-NC 4.0

Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada

Jenna Langlois, Nadia Fairbairn, Didier Jutras-Aswad, Bernard Le Foll, Keith Ahamad, Ron Lim, M Eugenia Socías iD

Substance Use & Addiction Journal · 2025

DOI: 10.1177/29767342241298044 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Substance Use & Addiction Journal, 2025. Verfasst von Jenna Langlois und 6 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Centre on Substance Use, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Methadone, Buprenorphine, Naloxone Drug Combination, Opioid-Related Disorders, Methamphetamine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Research Initiative on Substance Misuse, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It has been suggested that opioid agonist therapy (OAT) may have a secondary benefit of reducing methamphetamine/amphetamine use. However, current evidence is limited and conflicting, and little is known on the impacts of different OATs on methamphetamine/amphetamine use. The aim of this study was to examine the comparative effectiveness of buprenorphine/naloxone and methadone on methamphetamine/amphetamine use among individuals with opioid use disorder (OUD) initiating OAT in Canada.

Methods

Data for this study were derived from a 24-week pan-Canadian pragmatic trial conducted between 2017 and 2020 comparing supervised methadone versus flexible take-home dosing buprenorphine/naloxone models of care among OUD. Generalized linear mixed models were used to evaluate the independent effect of treatment (ie, methadone or buprenorphine/naloxone) and time in treatment (ie, week 2 through 24, continuous) on methamphetamine/amphetamine use (measured by urine drug test and self-report using Timeline Follow-Back).

Results

The sample included 210 participants that initiated OAT, of which 130 (61.9%) were using methamphetamine/amphetamine at baseline. In multivariable analysis, neither treatment nor time in treatment were significantly associated with the odds of methamphetamine/amphetamine use (adjusted odds ratio [AOR] = 0.61, 95% confidence interval [CI] = 0.34-1.08, P = .092; and AOR = 0.73, CI = 0.40-1.28, P = .283, respectively). No interaction between treatment and time in treatment was observed for methamphetamine/amphetamine use ( P = .367).

Conclusion

Methamphetamine/amphetamine use was common among this sample of people with OUD initiating OAT in Canada. Over the 24-week study period, buprenorphine/naloxone and methadone were not associated with a quantifiable change in methamphetamine/amphetamine use among this sample population. The observation of less methamphetamine/amphetamine use in the buprenorphine/naloxone arm warrants further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneBuprenorphine, Naloxone Drug CombinationOpioid-Related DisordersMethamphetamineAmphetamine-Related DisordersOpiate Substitution TreatmentNarcotic AntagonistsHumansMaleFemaleAdultCanadaMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

amphetaminebuprenorphine/naloxoneclinical trialmethadonemethamphetamineopioid use disorderprescription opioids

Substanzen

MethadoneBuprenorphine, Naloxone Drug CombinationMethamphetamineNarcotic Antagonists

Autor:innen und Institutionen

  • British Columbia Centre on Substance Use, Vancouver, BC, Canada.
  • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
  • Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
  • Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
  • Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: M Eugenia Socías

Förderung

  • Canadian Research Initiative on Substance Misuse
  • Canadian Institutes of Health Research

Zitieren

APA

Langlois, J., Fairbairn, N., Jutras-Aswad, D., Le Foll, B., Ahamad, K., Lim, R., & Socías, M. E. (2025). Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada. Substance Use & Addiction Journal. https://doi.org/10.1177/29767342241298044

Vancouver

Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, et al. Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada. Substance Use & Addiction Journal. 2025. doi:10.1177/29767342241298044

BibTeX
@article{Langlois2025,
  author = {Langlois, Jenna and Fairbairn, Nadia and Jutras-Aswad, Didier and Le Foll, Bernard and Ahamad, Keith and Lim, Ron and Socías, M Eugenia},
  title = {Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada},
  journal = {Substance Use & Addiction Journal},
  year = {2025},
  doi = {10.1177/29767342241298044}
}
Kostenlos starten →